|Pack Size||Qty||Price Per Pill or Unit||Price||Offer|
|30 Tablet/s||US$ 0.19||US$ 5.65||
|60 Tablet/s||US$ 0.19||US$ 11.28||
|90 Tablet/s||US$ 0.19||US$ 16.92||
|US Brand Name||Isosorb Mono|
|Generic Name||Isosorbide Mononitrate|
|Manufacturer||ESP Pharma, Inc|
Ismo 20 mg is a sustained release formulation for the treatment of chronic stable angina pectoris. In patients with chronic stable angina, this medication provides effective antianginal prophylaxis for up to 12 hours. The available data from various clinical trials suggest that Ismo is a useful and convenient drug treatment for patients with chronic stable angina pectoris. Isosorbide mononitrate extended-release tablets should not be given to patients who have shown hypersensitivity or adverse reactions to other nitrates or nitrites. After oral administration of Isosorbide, a maximum concentration of the active ingredient is achieved in 20 to 60 minutes.
The standard dose is Ismo 20 mg, one tablet twice daily, increasing to 1 to three tablets twice daily. To prevent or minimize the headache, it is recommended that the dose is reduced to half a tablet twice daily.
Treatment of Ismo 20 mg is normally a long-term treatment. Swallow the tablet with plenty of fluids. If required, one tablet is used shortly before going to sleep. A significant drop in blood pressure may occur with this small dose of Isosorbide. Therefore, the medicine should be used with caution in patients who are already hypotensive. It is always a good decision to use your heart and blood pressure medicine under medical supervision.
Ismo 20 mg should not be used in marked hypotension, acute circulatory failure, severe anaemia, and hypovolaemia. Concomitant intake of tadalafil, vardenafil, and sildenafil is contraindicated; in this case, a hypotensive effect may occur. The medicine should not be used in case of hypersensitivity to Isosorbide mononitrate, other nitrate compounds, or other inactive ingredients of the formulation. Ismo tablets should be used with caution in certain conditions, including constrictive pericarditis, hypertrophic obstructive cardiomyopathy. The safety and effectiveness of this heart medication in paediatric patients have not been established. The extended-release tablet did not include sufficient information on patients aged 65 and over to determine whether they respond differently from younger patients. The dose selection for an elderly patient should usually start at the low dose, reflecting the greater frequency of decreased renal, hepatic or heart function. Elderly patients may be more prone to hypotension and may be at greater risk of falling at therapeutic doses of nitroglycerin. In elderly patients, nitrate medications may cause worsening of angina caused by hypertrophic cardiomyopathy.
During the initial days of the treatment, nitrate-induced headaches may occur. The side effect resolves after a few days of constant intake. Common side effects during initial use include a fall in blood pressure, also known as orthostatic hypotension. The condition may be accompanied by a reflex increase in the pulse rate and feelings of dizziness and weakness. Such symptoms generally resolve during treatment, and they are usually mild to moderate, improves with long term therapy and rarely leads to treatment withdrawal. Other side effects include a significant drop in blood pressure with worsening of angina pectoris symptoms.